Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...